Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACET vs CDROW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACET Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–0 Matrix Metrics)

ACET Overall Winner 6-Pillar Tally: ACET 4 – 1 CDROW (1 Tie) Matrix Metrics: ACET 8 – 0 CDROW

As of Nov 20, 2026, Adicet Bio, Inc. (ACET) is the stronger overall head-to-head candidate over Codere Online Luxembourg, S.A. Warrants (CDROW) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACET carries a Unified Composite Score of 40.1/100 (SELL) at $2.14 (N/M Forward P/E, 0.0% operating margin), whereas CDROW carries 31.8/100 (SELL) at $0.03 (N/M Forward P/E, N/A operating margin).

  • Defensive Composite Rating Caution: Although ACET compares more favorably head-to-head, both ACET (40.1/100 SELL) and CDROW (31.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ACET is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 13.6); meanwhile CDROW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACET vs CDROW
ACET NASDAQ Head-to-Head Winner
Adicet Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.14
-13.01% 1D
Market Cap $23.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.93β · 60% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 44.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.9%), weak momentum, RSI 14
RSI-14: 13.6 · SMA20: $3.07 · SMA50: $5.23
CDROW NASDAQ
Codere Online Luxembourg, S.A. Warrants
Institutional Equity
$0.03
-9.83% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.28β · 668% Vol
Unified Composite Score
31.8 / 100 SELL
Tech 5.0 Fund 32.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.6% over 20 days), RSI 65
RSI-14: 65.2 · SMA20: $0.82 · SMA50: $0.77

6-Pillar Scorecard Institutional Category Breakdown (ACET 4 – 1 CDROW)

Columns: Metric · ACET · CDROW
1. Valuation Multiples ACET
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.82x N/M
EV / Revenue N/M N/M
2. Growth & Scale ACET
Revenue Growth (YoY) -100.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $23.0M N/A
3. Profitability & Quality ACET
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -85.9% N/A
4. Balance Sheet & Cash Flow ACET
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $15M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CDROW
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 230.4% (27th %ile) N/A (N/A)
Put/Call OI Skew 1.41x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACET (8) vs CDROW (0)
Institutional Metric ACET CDROW Criterion Row Edge
Market Capitalization
Scale
$23.0M N/A Larger Scale ACET
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% N/A Higher Growth ACET
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin ACET
Net Profit Margin
Profitability
0.0% N/A Higher Margin ACET
Return on Equity (ROE)
Capital Efficiency
-85.9% N/A Higher ROE ACET
52-Week Range Position
Momentum
18% ($0–$10) 2% ($0–$1) Stronger Trend ACET
Beta / 30D Volatility
Risk Regime
1.93β · 60% Vol 2.28β · 668% Vol Lower Realized Risk ACET
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 31.8 / 100 (SELL) Higher Composite ACET
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.82x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($15M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACET +25.19 pp
ACET: -62.72% · CDROW: -87.91%
3M Horizon ACET +23.26 pp
ACET: -73.61% · CDROW: -96.87%
6M Horizon ACET +27.16 pp
ACET: -69.03% · CDROW: -96.19%
1Y Horizon ACET +366.96 pp
ACET: +270.76% · CDROW: -96.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACET vs CDROW. Trailing 12-month operating profitability (ACET 0.0% vs CDROW N/A) and valuation multiples (ACET N/M vs CDROW N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACET ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.9% · N/M
CDROW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACET BREAKDOWN
122d in phase · OBV DISTRIBUTION
Current IV 230.4%
IV Percentile 27th %ile
Put/Call OI Skew 1.41x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ACET Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDROW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDROW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACET Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $23.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDROW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACET vs CDROW Key Questions & Quantitative Answers

As of Nov 20, 2026, Adicet Bio, Inc. (ACET) is the stronger overall head-to-head candidate over Codere Online Luxembourg, S.A. Warrants (CDROW) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACET carries a Unified Composite Score of 40.1/100 (SELL) at $2.14 (N/M Forward P/E, 0.0% operating margin), whereas CDROW carries 31.8/100 (SELL) at $0.03 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although ACET compares more favorably head-to-head, both ACET (40.1/100 SELL) and CDROW (31.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ACET is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 13.6); meanwhile CDROW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACET leads the Growth & Scale pillar: ACET posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CDROW at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ACET generates N/A in USD-normalized revenue versus N/A for CDROW. In operating R&D and SG&A reinvestment, ACET deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CDROW.

ACET screens cheaper on headline valuation multiples. ACET trades at N/M Forward P/E, N/M Trailing P/E, 0.82x PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CDROW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACET (-85.9% ROE) versus CDROW (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ACET carries 230.4% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 1.41x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 60% Vol realized risk). By comparison, CDROW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.28β · 668% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.